TY  - JOUR
AU  - Sanz, Jaime
AU  - Bug, Gesine
AU  - Ciceri, Fabio
AU  - Craddock, Charles
AU  - Dillon, Richard
AU  - Esteve, Jordi
AU  - Porta, Matteo Giovanni Della
AU  - Heuser, Michael
AU  - de Leeuw, David C
AU  - Nagler, Arnon
AU  - Onida, Francesco
AU  - Roboz, Gail J
AU  - Ruggeri, Annalisa
AU  - Sánchez-Ortega, Isabel
AU  - Srour, Micha
AU  - Yakoub-Agha, Ibrahim
AU  - Buccisano, Francesco
TI  - Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.
JO  - The lancet / Oncology
VL  - 26
IS  - 11
SN  - 1470-2045
CY  - London
PB  - The Lancet Publ. Group
M1  - DKFZ-2025-02243
SP  - e586 - e596
PY  - 2025
AB  - Measurable residual disease (MRD) is a key predictor of relapse, the primary cause of treatment failure after allogeneic haematopoietic cell transplantation (allo-HCT) in acute myeloid leukaemia. This Policy Review, based on guidance from the European Society for Blood and Marrow Transplantation, provides practical recommendations for incorporating MRD assessment into clinical decision making during the transplantation process, the application of which remains challenging in acute myeloid leukaemia due to technical limitations and the limited availability of standardised, evidence-based approaches. Available methods include reverse transcription quantitative PCR, digital droplet PCR, next-generation sequencing, and multiparametric flow cytometry-chimerism-based approaches are under investigation. This Policy Review highlights the importance of MRD monitoring to enable timely, risk-adapted interventions that encompass both pre-transplantation and post-transplantation periods and can include tailoring conditioning intensity, donor selection, immunosuppression management, donor lymphocyte infusions, and pharmacological therapies such as FLT3 or IDH inhibitors, hypomethylating agents, venetoclax, or menin inhibitors. These recommendations aim to harmonise MRD-driven clinical practice and improve patient outcomes, while identifying key areas for future research.
KW  - Humans
KW  - Neoplasm, Residual
KW  - Hematopoietic Stem Cell Transplantation: standards
KW  - Hematopoietic Stem Cell Transplantation: adverse effects
KW  - Leukemia, Myeloid, Acute: therapy
KW  - Leukemia, Myeloid, Acute: pathology
KW  - Leukemia, Myeloid, Acute: genetics
KW  - Transplantation, Homologous
KW  - Europe
KW  - Transplantation Conditioning
KW  - Clinical Decision-Making
LB  - PUB:(DE-HGF)16
C6  - pmid:41167226
DO  - DOI:10.1016/S1470-2045(25)00426-7
UR  - https://inrepo02.dkfz.de/record/305584
ER  -